INTRODUCTION
Glioblastoma represents 15-20% of brain tumors and 50% of all gliomas (1) . A characteristic histopathologic hallmark of glioblastoma is marked cytologic heterogeneity of astrocytic tumor cells associated with necrosis and/or vascular endothelial proliferation (2, 3) . Molecular biologic studies indicate that glioblastoma is the common end point in the progression of grade 2 (low-grade) or grade 3 (anaplastic) astrocytomas (4, 5) . In the revised WHO classification of tumors of the central nervous system, glioblastoma is classified under the group of astrocytic tumors, grade 4, as opposed to its prior classification under embryonal tumors (6) .
Recent clinical and molecular studies indicate the two different genetic pathways leading to the development of glioblastomas: (a) final progression of lower grade astrocytoma, which arise due to p53 mutation, loss of heterozygosity (LOH) 17p, amplification of MDM2, CDK4, Rb mutation, LOH 10, and epidermal growth factor receptor (EGFR) amplification (7) (8) (9) (10) ; and (b) de novo from rapid malignant transformation of a normal glial cell due to LOH 10 and EGFR amplification (11, 12) . Another possible pathway of glioblastoma development is progression from other types of gliomas, such as oligodendrogliomas and oligoastrocytomas by way of genetic lesions of LOH 19q and 1p (13) (14) (15) , 9p and 10 (16) . Common association of EGFR amplification and p53 mutation is very rare in the first pathway (17, 18) .
Attempts have been made to link these different molecular genetic pathways in the development of glioblastomas to clinical features (17) (18) (19) (20) . Secondary glioblastomas derived from lower grade astrocytomas occurs in younger patients (mean age, 40.5 yr), while de novo glioblastomas tend to occur in older patients (mean age, 56.3 yr). However, these studies are primarily based on histopathologic diagnosis of glioblastomas without clinical distinction between primary and secondary etiologies.
p53 Mutation and Epidermal Growth Factor Receptor Overexpression in Glioblastoma
Recent molecular studies indicate two different genetic pathways leading to the development of glioblastoma; final progression of astrocytoma and de novo formation. To define the mutual relationships of cytogenetic changes in the pathogenesis of glioblastoma, molecular histopathologic alterations of p53 and epidermal growth factor receptor (EGFR) were evaluated by single stranded conformational polymorphion, reverse transcriptase-polymerase chain reaction and immunohistochemical stains in 15 primary and 21 secondary glioblastomas. Mutations in p53 gene and positive immunoreactivity to p53 protein (DO1) were more prevalent in secondary glioblastomas than in primary glioblastomas. A correlation between p53 mutations and p53 immunopositivities in glioblastomas was observed in 83.3% of the cases. All cases with positive p53 immunoreactivities showed p53 mutations; however, 13.9% of glioblastomas with p53 immunopositivities lacked the relevant mutations. EGFR amplifications were detected in 73.3% of primary glioblastomas and 9.5% of secondary glioblastomas (p<0.001). The concurrence of p53 mutation and EGFR amplification was revealed in only 2 out of 15 primary glioblastomas and none among the secondary glioblastomas. Immunoreactivities for EGFR were noted in 66.7% of primary glioblastomas and in 9.5% of secondary glioblastomas (p<0.001). A correlation between EGFR amplification and EGFR immunopositivity in glioblastomas was observed in 91.7% of the cases. These data indicate that EGFR amplification and p53 mutations are two independent genetic events in the development of glioblastomas. The aims of this study are to investigate molecular genetic abnormalities and their correlation to clinical criteria of primary and secondary glioblastomas and to define the mutual relationships between p53 mutation and EGFR amplification.
MATERIALS AND METHODS

Tumor samples
All tumor specimens were obtained from patients undergoing therapeutic operation for brain tumors at Chonnam National University Hospital from 1993 to 1998. Samples consisted of fresh-frozen tissues and paraffin-embedded tissue blocks, which were selected based on the adequacy for the molecular biologic and immunohistochemical studies.
Of the 36 cases, 15 patients had a clinical history of less than 3 months and were designated as primary glioblastomas. Twenty-one patients had secondary glioblastomas. Previous operations with initial histopathologic diagnosis of low grade astrocytomas and anaplastic astrocytomas were performed in 8 and 13 patients, respectively. The details of the clinical histories are shown in Table 1 and 2.
Immunohistochemistry for p53 and EGFR proteins
Paraffin-embedded tissue slices, 6 m in thickness, were immunostained by the avidin-biotin peroxidase (ABC) method (21) . Monoclonal antibodies for DO1 (Santa Cruz, U.S.A.) and EGFR-NCL (Novocastra, UK) were used at a titer of 1:100. DO1 binds to both mutant and wild type p53 proteins, and EGFR-NCL attaches to the extracellular ligand-binding domain of EGFR (22) . The tissue slices were deparaffinated with xylene. Endogenous peroxidase activity was quenched by incubation in 0.3% hydrogen peroxide in 10% methanol. The tissue slices were hydrated with graded alcohol, treated with 10% normal goat serum for 30 min, and then incubated with primary antibodies overnight at a temperature of 4℃ They were incubated with biotinylated anti-mouse IgG for 30 min at room temperature. The tissue slices for p53 protein immunostaining were incubated with streptavidin-alkaline phosphatase for 1 hr and developed with fast red TR salt (FRT). EGFRlabelled tissue slices were incubated with 1% avidinbiotinylated horseradish peroxidase in 10% normal goat serum for 1 hr at room temperature and developed in a mixture of 0.4 mg/mL diaminobenzidine (DAB) in 0.1% hydrogen peroxide solution for 40 sec. For negative controls, the primary antibodies were omitted in the process of immunostaining. All immunostained tissues were counterstained with hematoxylin solution for 5 min. After dehydration, the tissue was sealed with a universal mount (Research Genetics, U.S.A.) and examined under a light microscope. Nuclear staining of p53 was scored semi-quantitatively by counting 1,000 cells in the most prominently stained area of the tissue slides (23) . Staining of cell membrane for EGFR was marked as+or -in both low grade and high grade areas of the tissue slides (24) .
SSCP analysis for p53 mutations DNA was extracted from paraffin sections. For samples with positive immunostaining with DO1 antibody, the same areas were chosen for DNA extraction. For samples with negative immunostaining, DNA was extracted from Case number the lesion which was histologically typical of a glioblastomas, avoiding the peripheral infiltration zone. Primers for exons 4-9 of p53 were synthesized (Life Tec, Korea) according to published sequences (25) . Details of primers are shown in Table 3 . Polymerase chain reaction (PCR)-single stranded conformational polymorphism (SSCP) analysis was performed on 50 L of PCR mixture containing PCR reaction buffer (10 mM Tris-HCl, pH 8.8 at 25℃, 1.5 mM MgCl2, 50 mM KCl, 0.1% Triton X-100), 10 pmol of each primer, 50 M dNTPs, 3 L template DNA, 1 U DNA polymerase, and 0.1 Ci -32 P dCTP (NEN, U.S.A.). After adding 20 L of mineral oil (Sigma, U.S.A.), 35 cycles were executed. Each cycle consisted of denaturation (94℃) for 1 min, annealing for 60 sec (58℃ for exons 5/6 and 8/9, and 64℃ for exons 4 and 7), and extension for 2 min (72℃), and was carried out in an automated DNA Thermal Cycler (Perkin-Elmer, France). Forty microliter of stop buffer (95% formamide, 10 mM EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol) was added to the PCR product, and 2 L of the final mixture was sampled.
Samples were heated at 95℃ for 5 min and immediately loaded onto a 6% non-denaturating polyacrylamide gel containing 6% glycerol. Gels were run at 30 W for 3 hr, cooled by fan at room temperature, dried at 60℃, and autoradiographed for 12-48 hr.
RT-PCR for EGFR gene amplification
To investigate the expression level of EGFR in human glioblastoma, we employed a reverse transcriptase (RT)-PCR assay using EGFR primers. Total RNA was extracted from the tumor tissues of each glioblastoma patient. After the reverse transcription, EGFR primers were used for cDNA amplification. RNA integrity was confirmed with parallel RT-PCR amplification using -actin primers. PCR products were electrophoresed on agarose gels containing ethidium bromide and visualized by UV photography. The detailed procedure was as follows. Total RNA was extracted from frozen tissues using the LiCl/Urea method (26) . For cDNA synthesis, 3 g of total RNA was annealed to oligo (dT) 15 in 20 L total volume containing 4 L of 5 XM-MLV RT buffer (50 mM TrisHCl, pH 8.3, 7.5 mM KCl, 3 mM MgCl2, and 10 mM DTT), 0.5 mM dNTP, 20 U RNase and 200 U M-MLV RT (Promega, Germany) and was incubated at 37℃ for 1.5 hr. PCR mixture contained 1X PCR buffer (50 mM KCl, 10 mM Tris-HCl, pH 9.0, and 0.1% Triton X-100), 1 mM MgCl2, 0.2 M of each primer, 0.2 mM dNTP, 2.5 U of Taq DNA polymerase (Promega, Germany) and 1.5 g of cDNA in a final volume of 50 L. The amplification was performed in the DNA Thermal Cycler. Twenty-five PCR cycles were performed which consisted of 1 min at each temperature (94℃, 53℃, 72℃), except for the initial cycle (5 min at 94℃) and the final extension step (5 min at 72℃). Primer sequences for EGFR and -actin (reference gene) were as follows: 5′ -AGCCATGCCCGCATTAGCTC-3′ (5′ primer) and 5′ -AAAGGAATGCAACTTCCCAA-3′ (3′ primer) for EGFR (24) resulting in a 110-bp PCR product, 5′ -GACTATGACTTAGTTGCGTTA-3′(5′primer) and 5′ -GCCTTCATACATCTCAAGTTG-3′(3′primer) for -actin resulting in a 501-bp PCR product.
Statistical Analysis
All statistical analysis was performed using Statistical Package for the Social Sciences (SPSS/PC+ 7.5, Chicago, IL, U.S.A.). A p value of less than 0.05 was accepted as statistically significant. The Student t-test was used to evaluate differences in the age of patients and p53 labeling index (LI) between primary and secondary glioblastomas. The chisquare and Fisher' s exact tests were used to analyze differences in sex ratio, p53 mutations, p53 expression, EGFR amplification, and EGFR expression.
RESULTS
The results of this study are summarized in Table 4 . The mean ages of the patients with primary and secondary glioblastomas at the time of surgery were 50.2±8.4 yr and 41.5±10.4 yr respectively. The mean age of the patients with primary glioblastomas was significantly higher than that with secondary glioblastomas. The frequencies of both primary and secondary glioblastoma were higher in males than in females but the difference was not statistically significant.
p53 mutations were detected in 3 out of 15 (20.0%) primary glioblastomas (Fig. 1 ) and in 13 out of 21 (61.9%) secondary glioblastomas (p=0.014). All mutations were located between exons 5 to 9. Immunoreactivity to the p53 gene product was expressed on nuclei of glioblastoma cells. The distribution of p53-positive cells was very heterogenous in many cases (Fig. 2) , and there was no specific rela- tionship between p53 immunoreactivity and nuclear morphology. Immunoreactivity to DO1 was observed in 5 out of 15 (33.3%) primary glioblastomas, and in 17 out of 21 (81.0%) secondary glioblastomas (p=0.001). The mean p53 labeling index (LI) was 5.7±4.4 % and 10.8±8.3 % in primary and secondary glioblastomas, respectively (p=0.002). The correlative results between p53 mutations and p53 immunoreactivities were observed in 30 out of 36 (83.3%) glioblastomas (both positive, 44.4%; both negative, 38.9%). p53 labeling index mutations were observed in all p53-positive glioblastomas; however, 5 out of 36 (13.9%) glioblastomas revealed p53-immunopositivities without p53 mutations.
There were two cases with equivocal amplifications of EGFR by RT-PCR. One showed EGFR-positive immunoreactivity and the other was negative. Among the two, the one with positive immunoreactivity to EGFR was considered as positive EGFR amplification. EGFR amplifications were detected in 11 out of 15 (73.3%) primary glioblastomas and 2 out of 21 (9.5%) secondary glioblastomas (p<0.001). The concurrence of p53 mutation and EGFR amplification was observed only in 2 among 15 primary glioblastomas (Table 1) , and even absent in secondary glioblastomas (Table 2) . EGFR immunoreactivity was noted along the cell membrane of glioblastoma cells (Fig. 3) . Immunoreactivity for EGFR was noted in 10 out of 15 (66.7%) primary glioblastomas, and in 2 out of 21 (9.5%) in secondary glioblastomas (p<0.001). The correlative results between EGFR amplification by RT-PCR and EGFR immunoreactivity was observed in 33 out of 36 (91.7%) glioblastomas (both positive, 30.6%; both negative, 61.1%). Only one case revealed EGFR amplification without EGFR-positive glioblastoma cells. Among the 12 immunopositive cases, nine (75.0%) showed immunoreactivities in both low and high grade areas of glioblastomas while three (25.0%) showed only in high grade areas.
DISCUSSION
The recent molecular biologic studies of astrocytic tumors suggest that both activation of oncogenes and inactivation of tumor suppressor genes are involved in the development of glioblastomas. Von Deimling et al. indicated that there were two types of glioblastomas based on their molecular biologic pathogenesis (27) . The type 1 (secondary) glioblastoma occurs with LOH on chromosome 17p closely associated with p53 mutations and is more common in younger patients. The type 2 (primary) glioblastoma is characterized by higher frequencies of EGFR amplification and LOH on chromosome 10, and is common in elderly patients. The molecular features of primary and secondary glioblastomas were shown to be strongly correlated with the patients' clinical history in the recent studies (19, 27, 28) .
Although some studies support the classification of glioblastomas into two subtypes, only a few studies have analyzed molecular genetic alterations of EGFR and p53 in association with immunohistochemical findings on tumor samples. According to our results, the mutations of the p53 gene were found in 20.0% of primary glioblastomas and 61.9% of secondary glioblastomas. This observation is consistent with the high rate of p53 mutations reported by Watanabe et al. (29) . The high rate of p53 mutation in secondary glioblastomas might be due to the selection of biopsies according to the definite evidence of clinical progression from low grade or anaplastic astrocytomas. p53 protein immunoreactivity was noted in 33.3% and 80.1% of primary and secondary glioblastomas, respectively. In the presence of p53 gene mutations, positive staining of tumor cells for p53 protein might be expected; however, correlative studies of p53 protein immunohistochemistry and p53 gene mutation in glioblastomas reported a higher rate of protein expression than the gene mutation (30, 31) . The results of this study suggest that an alternative mechanism of p53 gene mutation can result in p53 protein accumulation. In this study, p53 LI was scored 5.7±4.4% and 10.8±8.3% in primary and secondary glioblastomas, respectively. There has been reported a wide range of nuclear staining of p53 in glioblastomas (23, 29) , and the difference might be attributed to the divergent monoclonal antibodies or to the scoring system used in each study.
EGFR is a member of the tyrosine kinase family of cell surface receptors and demonstrates various levels of expression throughout the cellular development and in a variety of different cell types. The receptor can transduce signals into the cells upon: 1) interaction with ligands such as EGF, transforming growth factor (TGF-), amphiregulin or heparin-binding EGF; 2) truncation or mutation of extracellular and/or intracellular domains; and 3) amplification of a basal receptor activity in the absence of ligand through cooperation with other cellular signaling pathways or nuclear events, such as an expression of v-erbB (32, 33) . EGFR has been implicated in human cancers, where it may contribute both to the initiation (glioblastoma) and progression (epithelial tumors) of the disease. It is frequently present in an amplified or over-expressed form in up to 30-40% of malignant gliomas (34, 35) .
According to the present study, the incidence of EGFR amplification was 73.3% and 9.5% in primary and secondary glioblastomas, respectively. Recent studies on EGFR amplification in glioblastoma were carried out by subgrouping as primary and secondary forms. ings for EGFR were observed in 66.7% and 9.5% of primary and secondary glioblastomas, respectively. Correlative studies between EGFR gene amplification and immunohistochemical finding are rare. A comparative study by Rieske et al. (37) reported 13 cases (45%) with immunopositivity for EGFR in a series of 28 glioblastomas, while amplification of EGFR gene was observed in 12 cases. In this study, only one case showed no EGFR immunoreactivity in the presence of EGFR gene amplification, and two cases demonstrated weak EGFR immunoreactivity without EGFR gene amplification. There seems to be no strict correlations between EGFR gene amplification and the protein overexpression. EGFR was relatively well expressed in both low grade and high grade areas of glioblastomas, despite a few exceptional cases. Three out of 12 EGFR immunopositive cases were not stained in low grade areas. Concerning with the morphological heterogeneity of glioblastoma, the other study (38) reported that genetic abnormalities seen in the low grade areas were conserved in the high grade areas suggesting that these morphologically different cellular subsets were derived from a common transformed clone. These findings might be helpful to detect the presence or absence of tumor cell infiltrations in the peripheral margin or edematous area of glioblastomas. In this study, the p53 mutation with concomitant EGFR gene amplification was observed in 13.3% of primary glioblastoma. There were no such cases among secondary glioblastomas. In line with this observation, Watanabe et al. reported only one case with such profile out of 20 secondary glioblastomas and none in 19 primary glioblastomas (29) . These data indicate that EGFR amplification and p53 mutation are two different genetic events in the development of glioblastomas.
